Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCCCNASDAQ:CGEMNASDAQ:PGENNASDAQ:RGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$1.42-1.4%$1.47$1.09▼$7.66$100.83M2.931.34 million shs1.06 million shsCGEMCullinan Therapeutics$7.67-6.0%$8.16$6.85▼$21.01$452.65M-0.04535,128 shs663,002 shsPGENPrecigen$1.45-2.7%$1.43$0.65▼$2.17$428.01M1.841.37 million shs2.11 million shsRGNXREGENXBIO$8.43-1.6%$8.75$5.04▼$15.36$422.85M1.09925,983 shs2.55 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics0.00%-15.48%+3.65%-33.02%-65.20%CGEMCullinan Therapeutics0.00%-10.92%-2.79%-9.98%-54.37%PGENPrecigen0.00%-4.61%+4.32%-19.89%-7.64%RGNXREGENXBIO0.00%-9.06%-14.50%+2.31%-30.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCCCCC4 Therapeutics1.8055 of 5 stars3.32.00.00.01.31.70.6CGEMCullinan Therapeutics1.723 of 5 stars3.50.00.00.02.21.70.6PGENPrecigen3.9578 of 5 stars3.51.00.04.72.61.70.6RGNXREGENXBIO4.3234 of 5 stars3.42.00.04.62.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCCCC4 Therapeutics 2.50Moderate Buy$12.00745.07% UpsideCGEMCullinan Therapeutics 3.00Buy$30.00291.13% UpsidePGENPrecigen 3.00Buy$6.00313.79% UpsideRGNXREGENXBIO 2.83Moderate Buy$31.63275.15% UpsideCurrent Analyst Ratings BreakdownLatest CCCC, RGNX, PGEN, and CGEM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025PGENPrecigenJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.006/11/2025CGEMCullinan TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$22.006/9/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.005/15/2025PGENPrecigenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/12/2025CGEMCullinan TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $24.004/17/2025RGNXREGENXBIOThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.004/16/2025CGEMCullinan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCCCC4 Therapeutics$35.58M2.83N/AN/A$3.06 per share0.46CGEMCullinan TherapeuticsN/AN/AN/AN/A$10.14 per shareN/APGENPrecigen$3.92M109.19N/AN/A$0.13 per share11.15RGNXREGENXBIO$83.33M5.07N/AN/A$5.24 per share1.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCCCC4 Therapeutics-$105.32M-$1.47N/AN/AN/A-259.60%-45.86%-28.96%7/30/2025 (Estimated)CGEMCullinan Therapeutics-$167.38M-$2.91N/AN/AN/AN/A-29.47%-28.19%8/14/2025 (Estimated)PGENPrecigen-$126.24M-$0.56N/AN/AN/A-3,728.87%-279.20%-79.74%8/13/2025 (Estimated)RGNXREGENXBIO-$227.10M-$3.11N/AN/AN/A-100.62%-53.29%-30.84%8/7/2025 (Estimated)Latest CCCC, RGNX, PGEN, and CGEM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PGENPrecigen-$0.08-$0.07+$0.01-$0.18$0.50 million$1.34 million5/12/2025Q1 2025RGNXREGENXBIO$0.41$0.12-$0.29$0.12$105.35 million$89.01 million5/8/2025Q1 2025CGEMCullinan Therapeutics-$0.78-$0.74+$0.04-$0.74N/AN/A5/7/2025Q1 2025CCCCC4 Therapeutics-$0.48-$0.37+$0.11-$0.37$3.54 million$7.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCCCC4 TherapeuticsN/AN/AN/AN/AN/ACGEMCullinan TherapeuticsN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCCCC4 TherapeuticsN/A5.705.70CGEMCullinan TherapeuticsN/A11.6211.62PGENPrecigenN/A3.533.53RGNXREGENXBION/A2.932.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCCCC4 Therapeutics78.81%CGEMCullinan Therapeutics86.31%PGENPrecigen33.51%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipCCCCC4 Therapeutics8.73%CGEMCullinan Therapeutics7.16%PGENPrecigen47.10%RGNXREGENXBIO12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCCCC4 Therapeutics15071.01 million64.81 millionOptionableCGEMCullinan Therapeutics3059.01 million54.79 millionOptionablePGENPrecigen190295.18 million156.15 millionOptionableRGNXREGENXBIO37050.16 million43.75 millionOptionableCCCC, RGNX, PGEN, and CGEM HeadlinesRecent News About These CompaniesAssenagon Asset Management S.A. Sells 283,399 Shares of REGENXBIO Inc. (NASDAQ:RGNX)June 16, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Stock Price Up 6.1% - What's Next?June 11, 2025 | marketbeat.comA Glimpse Into The Expert Outlook On Regenxbio Through 8 AnalystsJune 9, 2025 | benzinga.comREGENXBIO's (RGNX) Buy Rating Reaffirmed at Chardan CapitalJune 9, 2025 | marketbeat.comRegenxbio's RGX-121 Could Become The New Standard Of Care In Hunter SyndromeJune 6, 2025 | seekingalpha.comOtsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne updateJune 6, 2025 | biopharmadive.comRegeNXBio shares fall, despite positive new data on RGX-202June 6, 2025 | thepharmaletter.comRegenxbio’s Duchenne gene therapy data positive as shares falterJune 5, 2025 | bioworld.comRegenxbio Fails To Best Sarepta’s Elevidys With New Data for DMD Gene TherapyJune 5, 2025 | biospace.comREGENXBIO updates Phase 1/2 data for Duchenne candidateJune 5, 2025 | msn.comEarly Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, LongerJune 5, 2025 | benzinga.comREGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202June 5, 2025 | prnewswire.comREGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 5, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Shares Up 13.5% - Still a Buy?June 3, 2025 | marketbeat.comShort Interest in REGENXBIO Inc. (NASDAQ:RGNX) Expands By 21.9%June 3, 2025 | marketbeat.comBank of America Corp DE Reduces Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)June 3, 2025 | marketbeat.comREGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202June 2, 2025 | prnewswire.comTwo Sigma Advisers LP Acquires 112,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX)June 1, 2025 | marketbeat.comTwo Sigma Investments LP Acquires 263,495 Shares of REGENXBIO Inc. (NASDAQ:RGNX)June 1, 2025 | marketbeat.comFY2026 EPS Estimates for REGENXBIO Increased by AnalystMay 31, 2025 | marketbeat.comMillennium Management LLC Buys 1,061,187 Shares of REGENXBIO Inc. (NASDAQ:RGNX)May 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCCC, RGNX, PGEN, and CGEM Company DescriptionsC4 Therapeutics NASDAQ:CCCC$1.42 -0.02 (-1.39%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.42 +0.00 (+0.07%) As of 06/20/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Cullinan Therapeutics NASDAQ:CGEM$7.67 -0.49 (-6.00%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$7.66 0.00 (-0.07%) As of 06/20/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Precigen NASDAQ:PGEN$1.45 -0.04 (-2.68%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.45 0.00 (0.00%) As of 06/20/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.REGENXBIO NASDAQ:RGNX$8.43 -0.14 (-1.63%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$8.52 +0.09 (+1.01%) As of 06/20/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
